0218 Rigel
BioCentury & Getty Images

Deals

Rigel’s decision tree behind its RIPK1 Lilly deal 

The $125M up front will fuel development of the early stage IRAK program that Rigel has opted to keep

The $125M up front will fuel development of the early stage IRAK program that Rigel has opted to keep.

Feb 19, 2021 | 12:51 AM GMT

Rigel’s deal with Lilly for its clinical RIPK1 program will triple the biotech’s cash balance as it seeks to

Read the full 743 word article

How to gain access

Continue reading with a
two-week free trial.